Loading...

Bone Therapeutics

DB:BT1
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BT1
DB
€32M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Bone Therapeutics has significant price volatility in the past 3 months.
BT1 Share Price and Events
7 Day Returns
-3.8%
DB:BT1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-62.5%
DB:BT1
-10.2%
DE Biotechs
-6%
DE Market
BT1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bone Therapeutics (BT1) -3.8% -9.8% -19.8% -62.5% -78.9% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • BT1 underperformed the Biotechs industry which returned -10.2% over the past year.
  • BT1 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
BT1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Bone Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bone Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €3.575.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bone Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bone Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BT1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.86
ENXTBR:BOTHE Share Price ** ENXTBR (2019-04-18) in EUR €3.69
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bone Therapeutics.

DB:BT1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:BOTHE Share Price ÷ EPS (both in EUR)

= 3.69 ÷ -1.86

-1.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bone Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Bone Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Bone Therapeutics's expected growth come at a high price?
Raw Data
DB:BT1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bone Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bone Therapeutics's assets?
Raw Data
DB:BT1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.56
ENXTBR:BOTHE Share Price * ENXTBR (2019-04-18) in EUR €3.69
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:BT1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:BOTHE Share Price ÷ Book Value per Share (both in EUR)

= 3.69 ÷ 0.56

6.6x

* Primary Listing of Bone Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bone Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Bone Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bone Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bone Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
95.9%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Bone Therapeutics expected to grow at an attractive rate?
  • Unable to compare Bone Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Bone Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Bone Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BT1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BT1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 95.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BT1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BT1 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 31 1
2019-12-31 15 1
DB:BT1 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -13 -14
2018-09-30 1 -12 -15
2018-06-30 2 -11 -15
2018-03-31 2 -11 -14
2017-12-31 2 -11 -13
2017-09-30 2 -11 -13
2017-06-30 2 -12 -14
2017-03-31 2 -12 -13
2016-12-31 2 -11 -13
2016-09-30 2 -11 -13
2016-06-30 2 -10 -13
2016-03-31 2 -11 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Bone Therapeutics is high growth as no earnings estimate data is available.
  • Bone Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BT1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Bone Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BT1 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
DB:BT1 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.86
2018-09-30 -1.98
2018-06-30 -2.11
2018-03-31 -1.99
2017-12-31 -1.86
2017-09-30 -1.93
2017-06-30 -2.00
2017-03-31 -1.95
2016-12-31 -1.90
2016-09-30 -1.89
2016-06-30 -1.89
2016-03-31 -2.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bone Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Bone Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bone Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bone Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bone Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bone Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bone Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bone Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bone Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bone Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BT1 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.00 -14.22 3.66 12.88
2018-09-30 1.31 -14.54 3.56 12.90
2018-06-30 1.62 -14.85 3.47 12.91
2018-03-31 1.68 -13.80 3.43 13.02
2017-12-31 1.75 -12.75 3.39 13.12
2017-09-30 1.71 -13.23 3.26 13.59
2017-06-30 1.68 -13.70 3.13 14.07
2017-03-31 1.61 -13.35 3.14 13.86
2016-12-31 1.55 -12.99 3.16 13.65
2016-09-30 1.64 -12.86 3.48 13.65
2016-06-30 1.73 -12.73 3.81 13.65
2016-03-31 1.72 -13.44 3.47 13.28
2015-12-31 1.70 -14.14 3.14 12.91
2015-09-30 1.50 -12.48 2.55 11.52
2015-06-30 1.47 -10.06 1.72 9.63
2015-03-31 1.34 -7.89 1.53 8.79
2014-12-31 1.21 -5.73 1.35 7.96
2014-09-30 1.19 -5.20 0.98 7.69
2013-12-31 1.01 -4.08 0.62 6.82
2012-12-31 1.12 -3.69 0.35 6.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bone Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bone Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bone Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bone Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bone Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bone Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bone Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bone Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bone Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bone Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bone Therapeutics Company Filings, last reported 3 months ago.

DB:BT1 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.49 12.85 8.17
2018-09-30 4.49 12.85 8.17
2018-06-30 4.02 13.35 9.10
2018-03-31 4.02 13.35 9.10
2017-12-31 2.38 11.80 8.41
2017-09-30 2.38 11.80 8.41
2017-06-30 8.90 11.75 12.60
2017-03-31 8.90 11.75 12.60
2016-12-31 15.27 12.41 20.30
2016-09-30 15.27 12.41 20.30
2016-06-30 22.42 12.90 26.60
2016-03-31 22.42 12.90 26.60
2015-12-31 28.15 12.43 33.61
2015-09-30 28.15 12.43 33.61
2015-06-30 34.88 9.51 37.22
2015-03-31 34.88 9.51 37.22
2014-12-31 -9.49 18.94 11.58
2014-09-30 -1.81 8.42 1.74
2013-12-31 0.06 5.56 2.44
2012-12-31 2.64 4.31 4.82
  • Bone Therapeutics's level of debt (286.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (9924.3% vs 286.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bone Therapeutics has less than a year of cash runway based on current free cash flow.
  • Bone Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -5.1% each year.
X
Financial health checks
We assess Bone Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bone Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bone Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bone Therapeutics dividends.
If you bought €2,000 of Bone Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bone Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bone Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BT1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BT1 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bone Therapeutics has not reported any payouts.
  • Unable to verify if Bone Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bone Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bone Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bone Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bone Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bone Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bone Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Lienard
COMPENSATION €281,000
AGE 42
TENURE AS CEO 2.5 years
CEO Bio

Mr. Thomas Lienard, MBA, has been Chief Executive Officer of Bone Therapeutics SA since October 27, 2016. Mr. Lienard served as Interim Chief Executive Officer at Bone Therapeutics SA from October 11, 2016 to October 27, 2016 and served as its Chief Business Officer from November 9, 2015 October 10, 2016. Mr. Lienard assumes responsibility for activities regarding business development, business operations and strategic planning at Bone Therapeutics SA. Mr. Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr. Lienard served at Lundbeck, where he served as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. He served at Eli Lilly and Company, where he served various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr. Lienard started his career in 1999 as consultant at McKinsey & Company. He has been Director of Bone Therapeutics SA since October 27, 2016. Mr. Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) degree from Harvard Business School in Boston in 2004.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Bone Therapeutics management team in years:

0.5
Average Tenure
  • The average tenure for the Bone Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Thomas Lienard

TITLE
CEO & Director
COMPENSATION
€281K
AGE
42
TENURE
2.5 yrs

Jean-Luc Vandebroek

TITLE
CFO & Executive Director
TENURE
1.6 yrs

Benoit Moreaux

TITLE
Chief Scientific & Technology Officer
TENURE
0.2 yrs

Gunther De Backer

TITLE
Head of Corporate Communications & Investor Relations

Linda Lebon

TITLE
Chief Regulatory Officer
TENURE
0.5 yrs

Olivier Godeaux

TITLE
Chief Medical Officer
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Bone Therapeutics board of directors in years:

2.9
Average Tenure
69
Average Age
  • The average tenure for the Bone Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jean Stéphenne

TITLE
Chairman of the Board
AGE
69
TENURE
1.2 yrs

Thomas Lienard

TITLE
CEO & Director
COMPENSATION
€281K
AGE
42
TENURE
2.5 yrs

Jean-Luc Vandebroek

TITLE
CFO & Executive Director
TENURE
0.8 yrs

Roland Baron

TITLE
Independent Director & Member of Scientific Advisory Board
AGE
73
TENURE
4.3 yrs

Michel de Balzac

TITLE
Non-Executive Director
TENURE
3.3 yrs

David Scadden

TITLE
Member of Scientific Advisory Board
AGE
65

Joseph Lane

TITLE
Member of Scientific Advisory Board

Steven Goldring

TITLE
Member of Scientific Advisory Board
AGE
74

Sundeep Khosla

TITLE
Member of Scientific Advisory Board

Jean-Paul Prieels

TITLE
Independent Director
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Bone Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bone Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion; and PREOB, an autologous bone cell therapy product that is in Phase III development for the treatment of osteonecrosis of the hip. Bone Therapeutics SA was founded in 2006 and is based in Gosselies, Belgium.

Details
Name: Bone Therapeutics SA
BT1
Exchange: DB
Founded: 2006
€32,081,893
8,694,280
Website: http://www.bonetherapeutics.com
Address: Bone Therapeutics SA
rue Auguste Piccard, 37,
Gosselies,
Hainaut, 6041,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR BOTHE Ordinary Shares Euronext Brussels BE EUR 03. Feb 2015
OTCPK BNZP.F Ordinary Shares Pink Sheets LLC US USD 03. Feb 2015
DB BT1 Ordinary Shares Deutsche Boerse AG DE EUR 03. Feb 2015
LSE 0R55 Ordinary Shares London Stock Exchange GB EUR 03. Feb 2015
Number of employees
Current staff
Staff numbers
94
Bone Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/02
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.